Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rocket Pharmaceuticals (RCKT) Research & Development (2016 - 2025)

Rocket Pharmaceuticals (RCKT) has disclosed Research & Development for 10 consecutive years, with $29.3 million as the latest value for Q4 2025.

  • Quarterly Research & Development fell 21.44% to $29.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $142.0 million through Dec 2025, down 17.07% year-over-year, with the annual reading at $142.0 million for FY2025, 17.07% down from the prior year.
  • Research & Development hit $29.3 million in Q4 2025 for Rocket Pharmaceuticals, down from $34.1 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $51.4 million in Q2 2023 to a low of $24.5 million in Q2 2021.
  • Historically, Research & Development has averaged $39.5 million across 5 years, with a median of $41.6 million in 2022.
  • Biggest YoY gain for Research & Development was 82.95% in 2021; the steepest drop was 34.09% in 2021.
  • Year by year, Research & Development stood at $33.0 million in 2021, then surged by 51.55% to $50.0 million in 2022, then fell by 16.57% to $41.7 million in 2023, then dropped by 10.51% to $37.4 million in 2024, then dropped by 21.44% to $29.3 million in 2025.
  • Business Quant data shows Research & Development for RCKT at $29.3 million in Q4 2025, $34.1 million in Q3 2025, and $42.7 million in Q2 2025.